Association of CYP1B1 genetic polymorphism with incidence to breast and lung cancer
Citation
J. Watanabe et al., Association of CYP1B1 genetic polymorphism with incidence to breast and lung cancer, PHARMACOGEN, 10(1), 2000, pp. 25-33
Categorie Soggetti
Pharmacology & Toxicology
Journal title
PHARMACOGENETICS
SICI code
0960-314X(200002)10:1<25:AOCGPW>2.0.ZU;2-B
Abstract
Cytochrome P450 1B1 (CYP1B1) participates in the metabolic activation of a
number of procarcinogens including benzo[a]pyrene and the hydroxylation of
17 beta-estradiol at the C-4 position, In this study, we investigated the a
ssociation between CYP1B1 genetic polymorphism and breast or lung cancer in
cidence. The Ala-Ser polymorphism at codon 119 in presumed substrate recogn
ition site 1 was significantly associated with the incidence of breast or s
quamous cell carcinoma of the lung, On the other hand, Leu-Val polymorphism
at codon 432 did not show any association to the cancers. An allele contai
ning both Ala and Leu simultaneously, comprised 75% of alleles among 315 Ja
panese healthy controls, was significantly inversely associated with breast
cancer incidence. When expressed in a recombinant system, this CYP1B1 cDNA
showed the lowest 17 beta-estradiol 4-hydroxylase activity among four diff
erent variant forms of CYP1B1, Thus, inter-individual differences in activa
tion of procarcinogens or metabolism of oestrogen originating from genetic
polymorphisms of the human CYP1B1 gene may contribute to the susceptibility
of human cancers. Pharmacogenetics 10:25-33 (C) 2000 Lippincott Williams &
Wilkins.